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A B S T R A C T
Background: A recent randomized controlled trial demonstrated the bioequivalence between
universally applicable and AB0 compatible transfusion plasma in healthy volunteers. There
was a limited change in coagulation factor levels and inhibitors before and after plasma-
pheresis and subsequent plasma transfusion. The aim of this extension trial was to investigate
the true capacity of these plasma products to restore baseline levels of coagulation factors
and inhibitors after plasma depletion in comparison to haemodilution induced by infu-
sion of albumin solution.
Materials and methods: Fourteen healthy subjects, who completed both plasma transfu-
sion periods, underwent an additional plasmapheresis (600 mL) followed by an infusion
of 1200 mL albumin (3.125%) in a third period.
Results: The ﬁbrinogen levels, as well as other clotting factors (FII, FV, FVII and FXI), de-
creased by 10% after plasmapheresis, and subsequent infusion of albumin solution further
aggravated this drop in clotting factors to approximately 20–25%. The clotting factors with
a long half-life were not even restored 24 hours after infusion of albumin solution, whereas
those with a short half-life were replenished by endogenous synthesis within 24 hours.
In contrast, transfusion of either plasma product rapidly restored all clotting parameters
and inhibitors (protein S and plasmin inhibitor) immediately after transfusion.
Conclusion: This study demonstrates that albumin solution induces an enhanced dilution
of clotting factors and inhibitors, whereas both plasma products quickly compensated for
the experimental loss of these plasma proteins.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
A recent randomized, double blind trial (hereafter re-
ferred to as the core study) demonstrated the bioequivalence
between a pharmaceutical grade, universally applicable,
pathogen safeguarded plasma (Uniplas LG) and its parent
compound (Octaplas LG) in healthy individuals. This core trial
also demonstrated the absence of haemolytic transfusion
reactions after transfusion of universal plasma [1].
However, the changes in coagulation factor levels and in-
hibitors throughout the procedure of plasmapheresis (PPh;
600 mL of plasma was removed) and subsequent transfu-
sion of 1200 mL plasma was rather small. For example, the
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observed decrease in ﬁbrinogen averaged 13% after PPh,
although a 25% decrease in plasma coagulation factors was
expected. Likewise, ﬁbrinogen increased by only 6% after
transfusion of 1200 mL plasma (Fig. 1), although a greater
rise in ﬁbrinogen was expected based on the concentra-
tion of clotting factors in the plasma products (90% of
normal). As both plasma products were active treatments
and similar in terms of protein content and plasma colloid-
osmotic pressure, the active-control design of the study did
not provide any control to explore possible changes in
plasma proteins throughout such a procedure.
We hypothesized that ﬂuid redistribution may have oc-
curred following PPh and/or plasma transfusion, and was
responsible for the lowerthanexpectedobservedeffects inboth
directions. Toaddress this issueexperimentally, the core study
was augmented by a third control period (extension arm), in
whichvolunteers receivedan infusionof 1200mLalbumin so-
lution after PPh, instead of plasma. Hence, the aims of the
extension study and the overall analysis of the three periods
were to validate the experimental model and setup to in-
creaseassaysensitivity, inorder to investigate the truecapacity
of these plasma products to restore coagulation factor levels
and inhibitors after experimental plasma depletion.
As albumin supports plasma colloid-osmotic pressure,
it is often administered as a resuscitation ﬂuid [2]. However,
there is no clear consensus over the choice of resuscita-
tion ﬂuid. Fluid resuscitation with albumin was associated
with higher mortality rates than was resuscitation with
saline in a post-hoc study of patients with traumatic brain
injury [3]. However, the use of albumin-containing solu-
tions was associated with lower mortality compared with
other ﬂuid resuscitation regimens in a meta-analysis of
studies with septic patients [4]. Finally, no substantial dif-
ference between crystalloids and colloids was seen in any
important patient-centred outcome in 6997 critically ill pa-
tients [5]. Thus, it was also of interest to compare the effects
of an infusion of 1200 mL albumin solution with plasma on
coagulation parameters from the perspective of albumin as
a potential resuscitation ﬂuid.
2. Subjects and methods
The core study and subsequent amendments were
approved by the Ethics Committee of the Medical Univer-
sity of Vienna and the national authority (Österreichische
Agentur für Gesundheit und Ernährungsmittelsicherheit:
AGES), and was conducted in compliance with the regula-
tions of Good Clinical Practice (CPMP/ICH/135/95), and the
Declaration of Helsinki 2008. All subjects re-consented in
writing before inclusion into the extension study arm.
2.1. Study design and subject population
The objectives of this extension study were to compare
the recovery of clotting factors and inhibitors of Uniplas LG
and Octaplas LG, reported in the core study, with that of
albumin solution (primary objective) and to compare the
safety and tolerability of the pathogen safeguarded plasmas
with those of an albumin infusion (secondary objective).
Subjects with blood group Owere excluded, because they
were not expected to be at risk of incompatibility after trans-
fusion of Uniplas LG. Exclusion criteria and enrolment criteria
for the extension arm (third period) were the same as for
the core study [1], with the additional requirement that all
subjects entering the extension arm had to have com-
pleted the core study. Thus, only subjects who had received
full amounts of both plasma products (i.e., 1200mL Uniplas
LG and 1200 mL Octaplas LG [both Octapharma PPGmbH,
Vienna, Austria]) in the core study were eligible for the ex-
tension study arm. This subgroup of eligible, healthy subjects
underwent similar procedures as in the previous core study
where they had received the two plasma products in a ran-
domized sequence (randomization faxed from a central
Fig. 1. Time courses of ﬁbrinogen levels. Differences of ﬁbrinogen levels relative to baseline (i.e., pre-plasmapheresis [PPh]) before and after transfusion
of bioequivalent plasma products or infusion of albumin solution up to 24 hours post-infusion. Data are presented as means ± SD.
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contract research organization oﬃce) after plasma removal
of 600 mL in a cross-over design. The characteristics of the
two products have been described previously [6–10]. Ac-
cording to the Austrian guidelines a maximum of 700 mL
(without anticoagulation) can be removed by plasmapher-
esis dependent on the donor’s weight; an equivalent removal
of volume before replacement would result in cardiovas-
cular adverse events, like hypotension and circulatory
collapse. While the trial was double blind for the ﬁrst two
periods, the third period was open label.
2.2. Study treatments and visits
After a standard PPh of 600 mL plasma, subjects re-
ceived 750mL albumin 5% + 450mL 0.9% NaCl (total volume
of 1200 mL and a ﬁnal albumin concentration of 3.125% to
mimic albumin contents of the transfused plasma prod-
ucts) according to the same procedures as in the core study;
these two solutions were mixed prior to infusion. An iden-
tical infusion speed was used (i.e., <1 mL/kg BW/min).
Subjects reported to the clinic again for a short examina-
tion and blood sampling 24 hours and 7 days after the
infusion of albumin solution.
All tests were performed according to standardized, rou-
tinely used laboratory assays, in ISO certiﬁed laboratories
of the hospital.
2.3. Biochemical endpoints
Recovery was assessed by coagulation and haemostatic
parameters (activated partial thromboplastin time [aPTT; ex-
pressed in s], prothrombin time [PT; expressed in %],
ﬁbrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI, protein S and
plasmin inhibitor), as previously described [1]. The param-
eters were evaluated before PPh, after the end of PPh, as well
as 15 minutes, 2 hours and 24 hours after infusion to in-
vestigate short (15 minutes after end of transfusion) and
longer recovery times (2 hours, 24 hours). Analysis of re-
covery was done for exploratory purposes only and no
primary eﬃcacy variable was deﬁned.
2.4. Safety endpoints
The following safety endpoints were determined:
(1) parameters of haemolysis: haemoglobin (Hb), hapto-
globin, free Hb and indirect bilirubin on a Hitachi Analyzer
using Roche Reagents (Sysmex G.m.b.H, Vienna, Austria);
(2) immune haematology: direct antiglobulin test (DAT) per-
formed on all blood samples with the DiaMed-ID Micro
Typing System (DiaMed, Cresier, Switzerland) (not mea-
sured 15 minutes post-transfusion in periods 1 and 2), and
Complement activation: C3c, CH50 and C4 (Dade Siemens
Diagnostics, Vienna, Austria); (3) haematological param-
eters: red blood cells (RBC), haematocrit, white blood cells
(WBC) and platelets were quantiﬁed on a Sysmex X2100 cell
counter (Roche, Vienna, Austria) (RBC, WBC and platelets
at baseline, before-PPh and at Visit 8 only). Clinical chem-
istry and urine analysis were also carried out.
2.5. Statistical methodology
No formal separate sample size estimation was carried
out for the extension study, but based on the observed vari-
ance and the estimated effect size of approximately 25% in
the albumin arm, it was estimated that a number of >12 sub-
jects should suﬃce for our study aims. In addition to raw
values of coagulation and haemostatic parameters, abso-
lute and relative differences compared to baseline values
(measured before any intervention, i.e., before the start of
the preceding PPh at visit 2, visit 5 and visit 10, respective-
ly) were calculated for each of the three treatment arms.
Moreover, treatment group ratios of relative changes were
also calculated. Descriptive statistics for each parameter at
post-transfusion time are provided and a time course of dif-
ferences is presented, including 95% conﬁdence intervals
(CIs). Statistical characteristics of each parameter are pre-
sented by treatment periods.
The change from the values measured before the start
and after the end of PPh to maximum (or minimumwhere
appropriate) was calculated for all treatment periods and
the Wilcoxon signed rank test was applied for differences
Dt1 – Dc and Dt2 – Dc where Dt1 is the value of a parameter
in the Uniplas LG treatment period, Dt2 is the value of a pa-
rameter in the Octaplas LG treatment period, and Dc is the
value of a parameter in the albumin treatment period. In
addition, theWilcoxon signed rank test was also applied for
differences Dt1 – Dt2 to optimize interpretation of study
results.
Although all evaluations and analyses performed using
the third treatment period were done in an exploratory
manner, p-values for the ratio of relative differences (i.e.,
Uniplas LG/albumin solution, Octaplas LG/albumin solu-
tion, Uniplas LG/Octaplas LG) were calculated. As the relative
difference of 15 minutes after transfusion to post-PPh re-
ﬂects quick recovery of coagulation factors, a focus was on
the p-value of this particular relative difference.
The comparison of the Hb change between treatment
arms was analyzed by the analysis of variance model with
treatment effect. Using the square root of residual mean
squares as an estimate of the variance, two-sided 95% CIs
for treatment differences of Hb change were calculated. Any
p-values were calculated only for exploratory purposes.
Other safety endpoints were analyzed descriptively
between the treatments, together with mean treatment dif-
ferences estimated along with 95% CIs for continuous
parameters. The statistical analysis was carried using SAS
software, version 9.1.
3. Results
Between 30th of January and 12th of June 2009, 30 sub-
jects (17 males, 13 females) were randomized and received
at least one study treatment in the core study. Twenty-
ﬁve subjects completed both treatment periods, of whom
14 (9 males, 5 females) agreed to participate in the exten-
sion study arm and were re-screened between 21st of
September and 14th of October 2009. Their mean age (±stan-
dard deviation [SD]) was 35 ± 8 years (range: 23–48 years)
and mean height, weight and body mass index were
179 ± 9 cm, 76 ± 15 kg and 23.9 ± 3.9 kg/m2, respectively.
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As all 14 subjects had received the full doses (1200 mL –
equivalent to 16.3 ± 3.1mL/kg) of plasma products in the core
study, they received the same dose of albumin solution
(16.3 ± 3.1 mL/kg).
All 14 subjects completed the core study and its exten-
sion; no relevant protocol deviations were reported in any
subject in any of the three treatment periods. Thus, no
subject was excluded from the eﬃcacy analysis and the
safety and per protocol populations were identical.
3.1. Eﬃcacy
3.1.1. Coagulation factors and global coagulation tests
A dilution effect occurred, due to the volume of ﬂuid
infused. This is best seen in the albumin solution treat-
ment period, in which a solutionwith similar plasma colloid-
osmotic pressure to that of plasma, but devoid of coagulation
factors and inhibitors, was infused. This dilution effect lasted
for about 24 hours or even longer and is best exempliﬁed
by the plasma concentrations of those coagulation factors
with long half-lives, such as ﬁbrinogen or FII (prothrom-
bin; Figs. 1 and 2).
Figs. 1–4 demonstrate a very rapid recovery (within 15
minutes) of coagulation factors after plasma transfusion, so
that relative differences of clotting factors to baseline were
close to 0 or positive at all measured time points. In con-
trast, they were consistently lower than baseline after
infusion of albumin solution (Figs. 1–4). Both plasma prod-
ucts almost completely restored baseline ﬁbrinogen levels,
whereas the infusion of albumin solution did not (p = 0.0001
plasma products vs. albumin).
Plasma levels of FII (Fig. 2), a coagulation factor of the
common terminal pathway, with a half-life of 48–60 hours,
showed a pattern similar to ﬁbrinogen. After an initial de-
crease due to the removal by plasmapheresis, prothrombin
levels continuously increased and were close to baseline 15
minutes after plasma transfusion, whereas they were
consistently below baseline after infusion of albumin so-
lution (p = 0.0001 plasma products vs. albumin). Changes
in FV and FX levels resembled those of FII (data not shown).
Factor VII, a coagulation factor of the extrinsic pathway,
also decreased initially after PPh and increased again along
with the transfused plasma (Fig. 3). The early effects of in-
fusion of albumin solution up to 2 hours were comparable
to the response seen with the other coagulation factors.
However, 24 hours after infusion of albumin solution, FVII
levels were comparable to those in the plasma transfusion
periods, due to the relatively short regeneration time of FVII
(<7 hours).
Plasma transfusion also quickly restored FXI, a coagu-
lation factor of the intrinsic pathway, after plasmapheresis,
whereas albumin solution induced a dilution effect that
lasted 24 hours or more (Fig. 4). Again, the dilution effect
of FXI was longer than for FVIII and FIX, because of their
shorter half-lives (data not shown).
After transfusion of the plasma products, the variation
in PT reﬂected the characteristic pattern observed in coag-
ulation factors of the extrinsic pathway (Fig. 5). A discrete
initial decrease (less than 10%) was seen following PPh due
to the removal of coagulation factors determining PT (i.e.:
FII, FV, FVII, FX ), which was followed by a small increase
15 minutes after plasma transfusion (levels were close to
preapheresis levels). Prothrombin time stabilized and re-
mained almost constant thereafter. In the albumin treatment
period, the initial decrease in PT due to plasmapheresis was
further accentuated. Prothrombin time was comparable to
the plasma transfusion periods after 24 hours, mainly
because the applied PT assay is very sensitive to FVII (Fig. 2).
aPTT is another global coagulation test which mea-
sures the intrinsic coagulation pathway (it reﬂects the
activity of FVIII, FIX, FXI and FXII). The loss of coagulation
factors did not translate into a remarkable change in aPTT
during any of the three treatment periods (data not shown).
The transfusion of plasma products decreased the aPPT by
Fig. 2. Time courses of prothrombin levels. Differences of prothrombin levels relative to baseline (pre-plasmapheresis [PPh]) before and after transfusion
of bioequivalent plasma products or infusion of albumin solution up to 24 hours post-infusion. Data are presented as means ± SD.
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2–3 s, while infusion of albumin solution increased the aPPT
by 1 s at 15 minutes.
3.1.2. Protein S and plasmin inhibitor
Protein S, a cofactor for protein C, and plasmin inhibi-
tor, a ﬁbrinolysis inhibitor, were also measured in the three
treatment periods (visit 2, visit 5 and visit 10).
Although mean values of protein S were consistently
within normal range in the plasma treatment periods, re-
covery of protein S after PPhwas somewhat slower than that
seen in coagulation factors. As expected, in the albumin
treatment period, protein S continued to decrease until after
the infusion of albumin solution (p = 0.0001 plasma prod-
ucts vs. albumin).
The same observation was made for plasmin inhibitor
with, however, lower relative differences to pre-PPh and
post-PPh in the plasma treatment periods and a more dis-
crete dilution effect caused by albumin (data not shown).
3.2. Safety results
3.2.1. Markers of a haemolysis transfusion reaction (HTR)
As expected, neither the plasma products nor albumin
solution induced a HTR, and not even a single positive DAT
test was observed in any of the three treatment periods. No
biological signs of HTR were detected in any of the three
treatment periods. All means of the tested markers, namely
Hb, haptoglobin, free Hb, indirect bilirubin, complement
Fig. 3. Time courses of FVII levels. Differences of FVII levels relative to baseline (pre-plasmapheresis [PPh]) before and after transfusion of bioequivalent
plasma products or infusion of albumin solution up to 24 hours post-infusion. Data are presented as means ± SD.
Fig. 4. Time courses of FXI levels. Differences of FXI levels relative to pre-plasmapheresis (PPh) measured before and after transfusion of bioequivalent
plasma products or infusion of albumin solution up to 24 hours post-infusion. Data are presented as means ± SD.
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activation and DAT were consistently within the normal
range. Variations were similar between the three treat-
ment periods.
3.2.2. Adverse events
In total, 35 adverse events were observed in 11 sub-
jects during the three treatment periods, of which 4 occurred
during the albumin solution treatment period (1 gastroin-
testinal disorder, 1 musculoskeletal and connective tissue
disorder, and 2 nervous system disorders). None of the
adverse events in the albumin solution treatment periodwas
considered to be possibly or probably related to treatment.
Abnormal laboratory values occurred with the same fre-
quency during the three treatment periods; they were all
clinically irrelevant.
4. Discussion
Uniplas LG is a blood group-independent, i.e., universal-
ly applicable, pathogen safeguarded, pooled plasma and can
therefore be administered irrespective of the recipient’s
blood group. In earlier clinical studies conducted in pa-
tients with pathological conditions, universal plasma was
equivalent to routinely used solvent/detergent (S/D) treated
plasma in terms of safety, tolerability and eﬃcacy [10,11].
As part of the product’s clinical development, a study has
also been conducted in healthy subjects, which compared
the safety and tolerability of Uniplas LG with an AB0 com-
patible parent plasma (Octaplas LG) in healthy volunteers
[1]. The ‘LG’ products denote further developments inmanu-
facturing of their respective earlier versions. The ‘LG’ process
was introduced to remove prions from S/D plasma, bymeans
of a speciﬁcally designed, aﬃnity ligand gel (LG) column,
and thereby reduce the risk of developing variant
Creutzfeldt–Jacob disease from transfused plasma. A recent
study done in the UK has demonstrated that the aﬃnity
chromatography procedure used in Octaplas LGmanufacture
did not adversely affect the known haemostatic quality of
the parent product [12].
We have previously demonstrated that both plasma prod-
ucts were equivalent with respect to safety, tolerability
and eﬃcacy and ruled out the occurrence of HTRs after
transfusion of the universal version [1]. Although their
bioequivalence was established, our analysis indicated
smaller than expected changes in coagulation factors. The
active-control design of the study did not provide any control
to explore a possible ﬂuid redistribution and/or dilution effect
following PPh and plasma transfusion.
To address this issue, the study was extended by a third
period, during which subjects received an infusion of
albumin solution as a control arm. Because of its protein
content, an albumin solution accounts for approximately 75%
of plasma colloid-osmotic pressure. It was therefore judged
more appropriate than physiological saline solution, which
lacks plasma colloid-osmotic pressure properties.
Infusion of albumin solution (1200 mL) further de-
creased clotting factors such as ﬁbrinogen, FII, FVII and FXI
(Figs. 1, 3, 4 and 5) after PPh, usually until 15 minutes post-
infusion. The dilution effect lasted ≥24 hours for clotting
factors with a long half-life such as ﬁbrinogen, the leading
determinant in dilution coagulopathy [13].
Plasmapheresis decreased the levels of coagulation factors
and inhibitors to a similar extent in all three periods.
However, plasma transfusion of either product rapidly in-
creased the plasma levels of coagulation factors and
inhibitors despite the dilution effect. Mean values of coag-
ulation factors were consistently signiﬁcantly higher in the
plasma product treatment periods than during the albumin
treatment period (Figs. 1–4). Baseline values of coagula-
tion factors were generally reached within 15 minutes to
2 hours following the end of plasma transfusion, indicat-
ing a quick recovery of coagulation factors.
These changes were followed closely by the changes in
both global coagulation tests. Thus, the changes in PT (Fig. 5)
Fig. 5. Time courses of prothrombin time (PT). Differences in prothrombin time (PT) relative to baseline (pre-plasmapheresis [PPh]) measured before and
after transfusion of bioequivalent plasma products or infusion of albumin solution up to 24 hours post-infusion. Data are presented as means ± SD.
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reﬂected FII, FV, FVII, FX and ﬁbrinogen activities. However,
aPTT showed an inverse pattern (mainly a decrease), because
a decrease in aPTT indicates an increase in the activity of
coagulation factors.
Our results are in line with a dilution effect of albumin
on FXI and FXIII in children undergoing craniofacial surgery
[14] and the correction of dilution coagulopathy by fresh-
frozen plasma in patients after major surgery [15].
Although the results cannot be immediately extrapo-
lated to clinical practice, they do have potentially interesting
implications. When plasma volume is critically jeopar-
dized, the use of a plasma transfusion as a volume substitute
has been considered contraindicated [16,17]. In contrast,
several conventional colloid solutions (e.g., hydroxyethyl
starch [HES], dextrans, gelatins and albumin) or crystal-
loids are widely used for blood volume replacement therapy.
Colloids are capable of rapidly restoring circulating volume
with a smaller infused volume than physiological saline. Al-
though HES solutions are increasingly preferred in the critical
care setting [18] interference in blood coagulation has limited
the clinical use of some preparations [19]. Furthermore, the
clinical utility of administering albumin, a colloid which is
considered a near optimal resuscitation ﬂuid because it
occurs naturally in plasma [20,21], is also a matter of con-
troversy, not least because of its cost. The discussions on
the relative merits of the various colloids arise because,
alongside their intravascular expansion properties, they have
a varying inﬂuence on other critical parameters, notably co-
agulation and renal function [22].
One immediate effect of the use of crystalloid or colloid
infusions in order to maintain normovolaemia in patients
experiencing blood loss is the dilution of clotting factor
concentrations, as indeed was seen in this trial. This has
clinical consequences because, clearly, impaired coagula-
tion is undesirable in patients with major blood loss. Even
moderate dilution with colloids compromises the coagu-
lation system in several ways, including impaired ﬁbrinogen
polymerization and decreased clot strength [23–28]. Clot
ﬁrmness is recognized as a precondition for arresting
bleeding [28].
Therefore, bleeding control will not be restored quickly
if a patient is only treated by an infusion of a colloid, such
as albumin, which is devoid of coagulation factors. Al-
though such infusions will replace the lost volume in critical
cases, without the additional use of plasma containing the
appropriate coagulation factors, the necessary levels of these
factors might never be achieved.
In conclusion, this experimental model is suitable for
demonstrating the equivalence of two transfusion plasmas
with regard to restoration of coagulation parameters
versus the dilution effect of albumin solution. It helps in
the interpretation of similar trials [29]. In contrast to albumin
solution, which induces a fairly long-lasting decrease of co-
agulation factors, both plasma products promptly restored
the levels of diluted coagulation factors and inhibitors.
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